175 related articles for article (PubMed ID: 20182637)
1. BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.
Clark-Knowles KV; O'Brien AM; Weberpals JI
J Oncol; 2010; 2010():891059. PubMed ID: 20182637
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and implications for response to chemotherapy in ovarian cancer.
Quinn JE; Carser JE; James CR; Kennedy RD; Harkin DP
Gynecol Oncol; 2009 Apr; 113(1):134-42. PubMed ID: 19168207
[TBL] [Abstract][Full Text] [Related]
3. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
Weberpals JI; Clark-Knowles KV; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(19):3259-67. PubMed ID: 18591560
[TBL] [Abstract][Full Text] [Related]
4. Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Dimitrova D; Ruscito I; Olek S; Richter R; Hellwag A; Türbachova I; Woopen H; Baron U; Braicu EI; Sehouli J
Tumour Biol; 2016 Sep; 37(9):12329-12337. PubMed ID: 27297669
[TBL] [Abstract][Full Text] [Related]
5. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes.
Clark-Knowles KV; Garson K; Jonkers J; Vanderhyden BC
Exp Cell Res; 2007 Jan; 313(1):133-45. PubMed ID: 17070800
[TBL] [Abstract][Full Text] [Related]
6. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas.
Clark-Knowles KV; Senterman MK; Collins O; Vanderhyden BC
PLoS One; 2009 Dec; 4(12):e8534. PubMed ID: 20046869
[TBL] [Abstract][Full Text] [Related]
7. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA; Tinker AV
BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
[TBL] [Abstract][Full Text] [Related]
8. DNA Repair Proteins as Therapeutic Targets in Ovarian Cancer.
López-Camarillo C; Rincón DG; Ruiz-García E; Astudillo-de la Vega H; Marchat LA
Curr Protein Pept Sci; 2019; 20(4):316-323. PubMed ID: 30215333
[TBL] [Abstract][Full Text] [Related]
9. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
[TBL] [Abstract][Full Text] [Related]
10. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
[TBL] [Abstract][Full Text] [Related]
13. Germline and Somatic
You Y; Li L; Lu J; Wu H; Wang J; Gao J; Wu M; Liang Z
Front Oncol; 2020; 10():295. PubMed ID: 32211327
[No Abstract] [Full Text] [Related]
14. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
[TBL] [Abstract][Full Text] [Related]
15. Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer.
Radosa MP; Häfner N; Camara O; Diebolder H; Mothes A; Winzer H; Jansen L; Dürst M; Runnebaum IB
Int J Gynecol Cancer; 2011 Nov; 21(8):1399-406. PubMed ID: 21897273
[TBL] [Abstract][Full Text] [Related]
16. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
Vencken PMLH; Kriege M; Hoogwerf D; Beugelink S; van der Burg MEL; Hooning MJ; Berns EM; Jager A; Collée M; Burger CW; Seynaeve C
Ann Oncol; 2011 Jun; 22(6):1346-1352. PubMed ID: 21228333
[TBL] [Abstract][Full Text] [Related]
17. HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.
Tierney BJ; McCann GA; Cohn DE; Eisenhauer E; Sudhakar M; Kuppusamy P; Hideg K; Selvendiran K
Cancer Biol Ther; 2012 Jul; 13(9):766-75. PubMed ID: 22801507
[TBL] [Abstract][Full Text] [Related]
18. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
19. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer.
Ma Y; Chen P; Drisko JA; Khabele D; Godwin AK; Chen Q
Oncol Lett; 2020 Apr; 19(4):2629-2638. PubMed ID: 32218813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
